Drug intelligence / Profile preview

HLK-3003

Development stage: Preclinical
Lead developer: HLK Pharmacin
Modality: Small Molecules

Overview

HLK-3003 is a pharmaceutical candidate currently under development by Pharmacin International (also known as HLK Pharmacin). It is being developed as a 505(b)(2) reformulation of an existing drug for the treatment of neurologic disorders. The 505(b)(2) regulatory pathway allows the developer to leverage existing safety and efficacy data of a previously approved drug while introducing a new formulation, dosage form, or indication. As of early 2024, HLK-3003 is in the formulation development stage. Specific details regarding the active pharmaceutical ingredient, biological target, and mechanism of action have not yet been disclosed by the company.

Beyond the preview

Go deeper on HLK-3003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-3003.

Explore the full profile